Mass High Tech quotes Konstantin Linnik in “IP lawyers say Myriad ruling may lead to lower costs, but less innovation”Print PDF
Konstantin Linnik, a member of the firm’s Intellectual Property and Life Sciences practice groups, was quoted in “IP lawyers say Myriad ruling may lead to lower costs, but less innovation” in Mass High Tech on June 13. The article discusses the highly anticipated decision issued today in Association for Molecular Pathology v. Myriad Genetics in which the Supreme Court unanimously ruled that isolated DNA sequences are not eligible for patent protection. The Court simultaneously held that cDNA can be patent eligible subject matter – as long as it is distinguishable from natural DNA.
Konstantin said that he believes the incentive to innovate will certainly be lessened as a result of the ruling. Biotechs will still pursue basic discoveries which can lead to gene-based diagnostic tests, he said, but “if the basic discovery is not protected, you’re going to drop the ball pretty early on.”
“It’s a pretty drastic decision, “he said. “It can be interpreted pretty broadly.”
To view the article, click here.